For most breast cancer patients, the period following treatment is defined by a singular, persistent anxiety: the wait for the next scan. Today, recurrence is typically confirmed only when a tumor grows large enough to appear on imaging or begins to cause physical symptoms. By then, the window for the most effective intervention has often narrowed.

A new study published in EMBO Molecular Medicine suggests that window is about to widen significantly. Researchers at Lund University have developed a blood-based method, dubbed Pathlight, that identifies circulating tumor DNA (ctDNA) with such precision that it can flag a relapse a median of 13.8 months before it becomes clinically visible. In some cases, the test identified the disease nearly four years before conventional methods.

The Genetic Fingerprint of a Tumor

The technology relies on the fact that every tumor possesses a unique genetic signature. By performing comprehensive genetic profiling at the time of diagnosis, researchers can identify specific DNA alterations. Pathlight then tracks these specific fragments in the bloodstream, allowing clinicians to detect residual tumor DNA even when the disease is far below the threshold of detection for current MRI or CT scans.

"The method is based on the idea that every tumor has a unique genetic fingerprint," said Lao Saal, a researcher at Lund University and the study's senior author. "By measuring these alterations in the patient's blood, we can detect extremely small amounts of residual tumor DNA with high precision."

Moving Beyond Traditional Benchmarks

The study followed 136 participants through chemotherapy and surgery, collecting blood samples at multiple intervals over six years. The results suggest the test could outperform current clinical standards.

Currently, doctors often rely on "pathological complete response" (pCR)—the absence of invasive cancer in the breast and lymph nodes at the time of surgery—to gauge how well a patient has responded to treatment. However, the study found that the presence of ctDNA in the blood after surgery was a more accurate predictor of future recurrence than pCR alone.

In 13 percent of patients, tumor DNA levels failed to decline during chemotherapy, a finding that was strongly associated with a high risk of relapse. This data could allow oncologists to pivot treatment strategies much earlier than is currently possible.

What Experts Say

While the technology is not yet a standard clinical tool, the implications for patient management are profound. Niklas Loman, a senior oncologist at Skåne University Hospital, suggests the test could eventually serve a dual purpose: identifying high-risk patients who need more aggressive therapy, and sparing low-risk patients from the toxicity of unnecessary, intensive treatments.

"These findings could change how breast cancer patients are monitored and treated in the future," Loman said. "With further research, the technology may provide opportunities to improve treatment for patients at high risk of recurrence."

Key Takeaways

  • The Pathlight blood test detected signs of breast cancer recurrence a median of 13.8 months before clinical symptoms or imaging evidence appeared.
  • The method tracks unique genetic "fingerprints" of tumors, allowing for the detection of residual DNA that traditional scans miss.
  • Researchers found that ctDNA levels are a more reliable predictor of survival and recurrence risk than current pathological response measures.

The Path Toward Clinical Adoption

The next phase for this technology involves larger-scale validation to determine how these findings translate into standardized clinical protocols. The research team is now looking toward multi-center trials to confirm these results across more diverse patient populations. For patients, the next major decision point will be the integration of these tests into routine follow-up care, which could shift the standard of care from reactive monitoring to proactive, molecular-level surveillance.